The motor symptoms of Parkinson's disease (PD) are widely thought to arise from an imbalance in the activity of the two major striatal efferent pathways following the loss of dopamine (DA) signaling. In striatopallidal, indirect pathway spiny projection neurons (iSPNs), intrinsic excitability rises following the loss of inhibitory D2 receptor signaling. Because these receptors are normally counterbalanced by adenosine A2a adenosine receptors, antagonists of these receptors are being examined as an adjunct to conventional pharmacological therapies. However, little is known about the effects of sustained A2a receptor antagonism on striatal adaptations in PD models. To address this issue, the A2a receptor antagonist SCH58261 was systemically administered to DA-depleted mice. After 5 days of treatment, the effects of SCH58261 on iSPNs were examined in brain slices using electrophysiological and optical approaches. SCH58261 treatment did not prevent spine loss in iSPNs following depletion, but did significantly attenuate alterations in synaptic currents, spine morphology and dendritic excitability. In part, these effects were attributable to the ability of SCH58261 to blunt the effects of DA depletion on cholinergic interneurons, another striatal cell type that co-expresses A2a and D 2 receptors. Collectively, these results suggest that A2a receptor antagonism improves striatal function in PD models by attenuating iSPN adaptations to DA depletion.
Introduction
The motor symptoms of PD have long been thought to be the product of an imbalance in the so-called direct and indirect striatal output pathways, leading to sustained inhibition of the motor thalamus and difficulty in initiating movement (Albin et al., 1989) . The best evidence for this hypothesis comes from studies showing that excitability of indirect pathway, striatopallidal spiny projection neurons (iSPNs), is increased following DA depletion. In vivo, the spontaneous activity and synaptic responsiveness of antidromicallyidentified iSPNs is elevated following depletion (Ballion et al., 2009; Mallet et al., 2006) and reducing their activity ameliorates the motor symptoms associated with DA depletion (Kravitz et al., 2010) . In brain slices from depleted mice, dendritic excitability is elevated in iSPNs and plasticity at excitatory glutamatergic synapses becomes biased toward long-term potentiation (LTP) (Day et al., 2006; Kreitzer and Malenka, 2007; Malenka and Bear, 2004; Shen et al., 2008) . This elevated excitability triggers a form of homeostatic plasticity (Turrigiano, 2007) , leading to a dramatic loss in iSPN excitatory synaptic connections and spines in the days following DA depletion (Day et al., 2006) , partially disconnecting the cerebral cortex from the striatum.
Diminishing the change in iSPN excitability following DA depletion should attenuate these adaptations and ameliorate motor impairment. Indirect and direct DA receptor agonists are commonly used to this end, but they often have unwanted side-effects or limited efficacy (Jenner, 2003b) . Adenosine A2a receptor (A2aR) antagonists are being examined as potential adjuncts to DA receptor based therapies (Hauser and Schwarzschild, 2005; Jenner, 2003a; Pinna et al., 2010) . A2aRs are expressed primarily in the striatum where they are found in iSPNs and cholinergic interneurons, both of which also robustly express D 2 receptors (D2Rs) (Hauser and Schwarzschild, 2005; Preston et al., 2000; Song et al., 2000; Surmeier et al., 2009 ). These two signaling pathways negatively interact at several levels (Canals et al., 2004; Morelli et al., 2007; Svenningsson et al., 1999) , suggesting that following DA depleting lesions, not only does D2R signaling fall, but A2aR signaling also rises. This antagonism also suggests that an elevation in A2aR signaling should reduce the ability of residual DA to effectively modulate iSPNs (Fuxe et al., 2007) . In agreement with this view, in human patients with PD, it has been hypothesized that A2aR antagonists will decrease the amount of levodopa required to achieve symptomatic relief and, in so doing, decrease dyskinesias (Hauser and Schwarzschild, 2005; Jenner, 2003a; Morelli et al., 2007) . In animal models, A2aR antagonists have similar effects (Hauser and Schwarzschild, 2005; Jenner, 2003a; Morelli et al., 2007) . Neurobiology of Disease 45 (2012) [409] [410] [411] [412] [413] [414] [415] [416] 
